HLSQ trades 188954.7% below Wall Street's consensus target of $38.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HLSQ achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Tessera Defense and Homeland Security Inc (HLSQ) has a Wall Street consensus price target of $38.00, based on estimates from 5 covering analysts. With the stock currently trading at $0.02, this represents a potential upside of +188954.7%. The company has a market capitalization of $415330.
Analyst price targets range from a low of $38.00 to a high of $38.00, representing a 0% spread in expectations. The median target of $38.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HLSQ trades at a trailing P/E of -0.0x. Analysts expect EPS to grow +86.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LSTALisata Therapeutics, Inc. | $9M | $1.04 | — | — | — | — | — |
ASMBAssembly Biosciences, Inc. | $446M | $22.50 | $51.67 | +129.6% | Buy | — | 12 |
ACXPAcurx Pharmaceuticals, Inc. | $4M | $0.99 | — | — | — | — | — |
PRAXPraxis Precision Medicines, Inc. | $8.5B | $305.06 | $611.69 | +100.5% | Buy | — | 18 |
CRSPCRISPR Therapeutics AG | $3.9B | $40.15 | $64.14 | +59.8% | Buy | — | 38 |
NTLAIntellia Therapeutics, Inc. | $1.1B | $9.78 | $20.71 | +111.8% | Buy | — | 39 |
EDITEditas Medicine, Inc. | $281M | $1.83 | $5.50 | +201.4% | Buy | — | 26 |
BEAMBeam Therapeutics Inc. | $2.1B | $20.65 | $66.00 | +219.6% | Buy | — | 28 |
PCVXVaxcyte, Inc. | $8.6B | $59.40 | $122.33 | +105.9% | Buy | — | 11 |
ILMNIllumina, Inc. | $30.7B | $202.61 | $252.73 | +24.7% | Buy | 37.4x | 50 |
Quick answers to the most common questions about buying HLSQ stock.
The consensus Wall Street price target for HLSQ is $38, representing 188954.7% upside from the current price of $0.0201. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
HLSQ has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies 188954.7% upside from current levels.
HLSQ's current price is $0.0201 with a consensus target of $38 (188954.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $38 for HLSQ, while the most conservative target is $38. The consensus of $38 represents the median expectation. These targets typically reflect 12-month expectations.
HLSQ is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HLSQ stock forecast based on 5 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $38 (bear case) to $38 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on HLSQ, with a "Buy" consensus rating and $38 price target (188954.7% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HLSQ analyst price targets range from $38 to $38, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.